MeiraGTx Financial Statements
NASDAQ: MGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MeiraGTx revenue and earnings
In fiscal 2025, MeiraGTx generated $81.4 million in revenue, up 144.6% from fiscal 2024, its 2nd consecutive year of revenue growth. MeiraGTx reported a net loss of $114.2 million, compared with a loss of $147.8 million a year earlier. Operating margin was -130.2%.
Diluted earnings per share came in at -$1.42. Over the last 5 fiscal years, MGTX's revenue has grown at a 39.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
MeiraGTx income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M | 15.56M | 13.29M | — | — |
| Revenue growth (YoY) | +144.57% | +137.42% | -11.95% | -57.77% | +142.25% | +17.09% | — | — | — |
| Operating Expenses | 187.36M | 197.49M | 151.08M | 132.28M | 110.46M | 78.12M | 71.56M | 78.10M | 31.68M |
| Research & Development | 129.62M | 119.48M | 103.78M | 85.72M | 66.69M | 33.91M | 24.88M | 33.62M | 22.36M |
| Selling, General & Admin | 57.74M | 78.01M | — | — | — | — | — | — | — |
| Operating Income | -105.97M | -164.21M | -137.06M | -116.36M | -72.76M | -62.55M | -58.27M | -78.10M | -31.68M |
| Interest Expense | 12.20M | 13.27M | 13.24M | 4.95M | 288.00K | 139.00K | 48.61K | 33.43K | 42.86K |
| Other Income (Expense) | — | — | — | — | — | — | — | 83.08K | — |
| Pretax Income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -83.34M | -31.04M |
| Income Tax | 0 | 0 | 0 | — | 0 | 0 | 0 | -474.39K | 0 |
| Net Income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -82.87M | -31.04M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.42 | -2.12 | -1.49 | -2.87 | -1.80 | -1.54 | -1.65 | -4.47 | -3.72 |
| EPS (Diluted) | -1.42 | -2.12 | -1.49 | -2.87 | -1.80 | -1.54 | -1.65 | -4.47 | -3.72 |
| Shares Outstanding (Basic) | 80.43M | 69.82M | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M |
| Shares Outstanding (Diluted) | 80.43M | 69.82M | 56.49M | 45.18M | 44.14M | 37.72M | 33.16M | 18.95M | 8.57M |
| EBITDA | -93.43M | -151.38M | -123.33M | -107.63M | -64.89M | -58.38M | -56.03M | -76.05M | -31.01M |
| Operating Margin | -130.20% | -493.44% | -977.82% | -730.87% | -192.99% | -401.94% | -438.37% | — | — |
| Net Margin | -140.31% | -444.10% | -599.46% | -814.16% | -211.03% | -372.63% | -411.87% | — | — |
This table shows 9 annual periods of MeiraGTx's income statement, from FY 2025 back to FY 2017, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow MGTX's reporting calendar. What is a income statement?